Eli Lilly and Company Reports Third-Quarter 2013 Results
Published: Oct 23, 2013
INDIANAPOLIS, Oct. 23, 2013 /PRNewswire via COMTEX/ -- -- Worldwide revenue increased 6 percent, driven by solid growth for Cymbalta, insulins, Animal Health, Alimta, Cialis and Trajenta.
-- Higher revenue and ongoing cost containment drove strong operating income growth.
-- Earnings per share totaled $1.11 for the third quarter of 2013.
Help employers find you! Check out all the jobs and post your resume.